Cryoport, Inc., a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd., a global contract development and manufacturing organization for cell and gene therapies, announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.
The collaboration combines Cryoport’s extensive capabilities and experience in meeting the logistics needs of the life sciences industry and Minaris’ expertise in contract manufacturing of regenerative medicine products including stem cells, gene therapy, biomaterials and engineered tissue.
Jerrell Shelton, CEO of Cryoport, commented, “We look forward to partnering with Minaris to provide cohesive supply chain solutions and manufacturing services for regenerative medicine products, starting from the collection of cells and tissues all the way to the delivery of these critical products and services to patients. This partnership perfectly aligns with our organization’s commitment to support the medical community and the people it serves.”
Also Read: Regel Therapeutics Appoints Stephen J. Farr as New Chief Executive Officer
Dr. Hiroto Bando, CEO of Minaris, added, “Ensuring secure transport, including the use and operation of specialized containers, as well as quality assurance, is essential for regenerative medicine products. By partnering with Cryoport, a best-in-class company that has considerable resources in all these areas, we will collaborate to provide high-quality services tailored to the exact needs of our customers. While this partnership is with Minaris’ Japan-based branch, we will collaborate to ensure that we can provide services to customers across the entire Minaris group.”
SOURCE: PRNewswire